Anti-programmed Death-ligand 1 Antibody-associated Eosinophilic Granulomatosis with Polyangiitis in Non-small Cell Lung Cancer
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA), a subtype of antineutrophil cytoplasmic antibody (ANCA)-related vasculitis, is rarely reported as an immune-related adverse event. We herein present the case of a 61-year-old woman with non-small cell lung cancer treated with durvalumab after definitive chemoradiotherapy. Following durvalumab treatment initiation, she experienced numbness in her hands and feet, and drop foot in her right ankle. She was subsequently diagnosed with peripheral neuropathy, eosinophilia, and myeloperoxidase-ANCA positivity, and had a history of asthma. Consequently, the patient was diagnosed as having EGPA. We report the first case of EGPA caused by durvalumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
Related
- When Eosinophilic Granulomatosis With Polyangiitis (EGPA) Looks Like Granulomatosis With Polyangiitis (GPA): Navigating a Complex Case of Anti-neutrophil Cytoplasmic Antibodies (ANCA) Vasculitis
- Eosinophilic Granulomatosis with Polyangiitis Complicated by Eosinophilic Chronic Rhinosinusitis Successfully Treated with Combination of Mepolizumab and Dupilumab
- Eosinophilic Granulomatosis with Polyangiitis Presenting with an Acute Hypersensitivity Pneumonitis-like CT Pattern: A Case Report
- Severe Cardiomyopathy Following Takotsubo Syndrome in a Patient Suffering from Eosinophilic Granulomatosis With Polyangiitis: A Case Report
- Coronary Vasospasm in Eosinophilic Granulomatosis With Polyangiitis
BibTeX
@article{sugimoto2026antiprogrammed,
title = {{Anti-programmed Death-ligand 1 Antibody-associated Eosinophilic Granulomatosis with Polyangiitis in Non-small Cell Lung Cancer}},
author = {Akira Sugimoto and Hiroyasu Kaneda and Satoshi Nozuchi and Toshikazu Mino and Itsuki Hasegawa and Megumi Mizutani and Hiroaki Nagamine and Yoshiya Matsumoto and Takako Oka and Yoko Tani and Kazuhiro Yamada and Tetsuya Watanabe and Kazuhisa Asai and Yoshiaki Itoh and Tomoya Kawaguchi},
journal = {Internal Medicine},
year = {2026},
month = aug,
doi = {10.2169/internalmedicine.6539-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/16/65_6539-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Anti-programmed Death-ligand 1 Antibody-associated Eosinophilic Granulomatosis with Polyangiitis in Non-small Cell Lung Cancer
AU - Akira Sugimoto
AU - Hiroyasu Kaneda
AU - Satoshi Nozuchi
AU - Toshikazu Mino
AU - Itsuki Hasegawa
AU - Megumi Mizutani
AU - Hiroaki Nagamine
AU - Yoshiya Matsumoto
AU - Takako Oka
AU - Yoko Tani
AU - Kazuhiro Yamada
AU - Tetsuya Watanabe
AU - Kazuhisa Asai
AU - Yoshiaki Itoh
AU - Tomoya Kawaguchi
PY - 2026
DA - 2026/08/15
JO - Internal Medicine
DO - 10.2169/internalmedicine.6539-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/16/65_6539-25/_article
AB - Eosinophilic granulomatosis with polyangiitis (EGPA), a subtype of antineutrophil cytoplasmic antibody (ANCA)-related vasculitis, is rarely reported as an immune-related adverse event. We herein present the case of a 61-year-old woman with non-small cell lung cancer treated with durvalumab after definitive chemoradiotherapy. Following durvalumab treatment initiation, she experienced numbness in her hands and feet, and drop foot in her right ankle. She was subsequently diagnosed with peripheral neuropathy, eosinophilia, and myeloperoxidase-ANCA positivity, and had a history of asthma. Consequently, the patient was diagnosed as having EGPA. We report the first case of EGPA caused by durvalumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
SN - 1349-7235
SN - 0918-2918
ER -